Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BevRam-GC: bevacizumab biosimilar plus ramucirumab and paclitaxel in unresectable advanced or recurrent gastric cancer
jRCT2031240512Phase 1Recruiting
- Sponsor
- Cancer Institute Hospital of JFCR
- Start
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bevacizumab, ramucirumab and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (5 arms), sponsored by Cancer Institute Hospital of JFCR. Primary endpoints: Incidence of Dose-Limiting Toxicity in Safety Part and Incidence of Adverse Events in Expansion Part. Started Jan 2025; status: recruiting.
02
Drugs
bevacizumabramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240512.